Nana Melanie, Majewska Agata, Rahim Mussarat, Geenes Victoria, Ovadia Caroline, Knight Marian, Heneghan Michael, Williamson Catherine
Department of Women and Children's Health, King's College London, London, UK.
Department of Obstetrics and Gynaecology, Institute of Mother and Child, Warsaw, Poland.
BJOG. 2025 Jun;132(7):935-943. doi: 10.1111/1471-0528.18107. Epub 2025 Mar 13.
Describe maternal/fetal outcomes of pregnant women with cirrhosis.
Prospective, national cohort study utilising the UK Obstetric Surveillance System between 1st June 2017 and 30th November 2020.
UK.
Pregnant women with cirrhosis.
Rates of adverse perinatal outcomes were compared with published rates for uncomplicated pregnancies. The prediction of adverse pregnancy outcomes by albumin-bilirubin (ALBI) score was determined.
Maternal and fetal outcomes.
52 eligible cases were reported (denominators represent available data for each outcome). Commonest causes included autoimmune hepatitis (12/50 (24.0%)), cholestatic disease (9/50 (18.0%)) and viral disorders (8/50 (18.0%)). Maternal decompensation occurred in seven women. Worst ALBI score predicted decompensation and maternal ICU admission (AUROC 0.80 (p = 0.03) and 0.81 (p = 0.03), respectively). Untreated varices were associated with increased rates of variceal bleed (p = 0.01). No women died. There were 42 live births (51.2% preterm), one stillbirth, and two neonatal deaths. The worst ALBI score in pregnancy predicted pre-term birth (AUROC 0.74 (p = 0.03)). Compared to a healthy population, women with cirrhosis were at increased risk of cholestasis in pregnancy (OR 29.4, 95% CI 13.8-61.6, p < 0.001), ICU admission (OR 42.5,95% CI 15.2-118.8, p < 0.001), pre-term birth (OR 13.2, 95% CI 7.1-24.4, p < 0.001), and babies with low birth weight (OR 12.0, 95% CI 6.5-22.0, p < 0.001), neonatal intensive care unit admission (OR 4.4, 95% CI 2.4-8.2, p < 0.001) and perinatal mortality (OR 15.8, 95% CI 4.9-51.3, p < 0.001).
Women with cirrhosis and their babies are at increased risk during pregnancy. The ALBI score predicts maternal decompensation, ICU admission, and pre-term birth.
描述肝硬化孕妇的母婴结局。
2017年6月1日至2020年11月30日期间利用英国产科监测系统进行的前瞻性全国队列研究。
英国。
肝硬化孕妇。
将不良围产期结局发生率与已发表的正常妊娠发生率进行比较。确定白蛋白-胆红素(ALBI)评分对不良妊娠结局的预测价值。
母婴结局。
报告了52例符合条件的病例(分母代表每个结局的可用数据)。最常见的病因包括自身免疫性肝炎(12/50(24.0%))、胆汁淤积性疾病(9/50(18.0%))和病毒性疾病(8/50(18.0%))。7名女性发生了母体失代偿。最差的ALBI评分可预测失代偿和入住产妇重症监护病房(AUROC分别为0.80(p = 0.03)和0.81(p = 0.03))。未治疗的静脉曲张与静脉曲张出血发生率增加相关(p = 0.01)。无女性死亡。有42例活产(51.2%为早产)、1例死产和2例新生儿死亡。孕期最差的ALBI评分可预测早产(AUROC 0.74(p = 0.03))。与健康人群相比,肝硬化女性孕期胆汁淤积风险增加(OR 29.4,95%CI 13.8 - 61.6,p < 0.001)、入住重症监护病房风险增加(OR 42.5,95%CI 15.2 - 118.8,p < 0.001)、早产风险增加(OR 13.2,95%CI 7.1 - 24.4,p < 0.001)、低出生体重儿风险增加(OR 12.0,95%CI 6.5 - 22.0,p < 0.001)、新生儿重症监护病房入住风险增加(OR 4.4,95%CI 2.4 - 8.2,p < 0.001)和围产期死亡率增加(OR 15.8,95%CI 4.9 - 51.3,p < 0.001)。
肝硬化女性及其婴儿在孕期风险增加。ALBI评分可预测母体失代偿、入住重症监护病房和早产。